Home Blog Page 1819

Olight to Unveil Next-Generation Tactical Optics and Lighting Systems at Milipol Paris 2025

By
Advertorial Desk
-

PARIS, FRANCE – Media OutReach Newswire – 13 November 2025 – Olight, a global leader in innovative tactical equipment, will showcase the latest evolution of its advanced combat solutions at Milipol Paris 2025, from November 18-21. Headlining the presentation at Hall 5A, Booth D001, is the OSIGHT X GN, the much-anticipated green dot variant in its established OSIGHT series of tactical optics

Engineered for superior performance, the OSIGHT X GN enhances the existing platform with a versatile green Multi-Reticle System (3 MOA Dot + 32 MOA Circle). Paired with a large field of view, it ensures rapid, precise target acquisition under diverse conditions. The optic retains the line’s signature features, including a durable OAL™ housing and an industry-first magnetic charging cover, reaffirming Olight’s commitment to setting new standards for reliability and convenience.

Complementing its flagship optic, Olight will feature the multi-functional ArkPro Series demonstrating Olight’s ecosystem approach. This compact 4-in-1 powerhouse integrates a pure floodlight, a spotlight, UV light, and a green laser. Olight is also announcing the Marauder Mini 2, which introduces new capabilities and extreme performance to its globally popular predecessor. Reaching up to 10,000 lumens in floodlight mode, it’s a compact searchlight built for search and rescue, security, and other professional outdoor applications.

In addition to these new models, Olight will feature its Baldr S tactical light. Highly compatible with a wide variety of compact and subcompact devices, it uses an adjustable, secure rail-mount system for a perfect fit. It pairs an adjustable green laser that aids in aiming with an 800-lumen white light that offers 130 meters of throw, as well as a low output setting and momentary-on for maximum tactical versatility. This updated portfolio underscores Olight’s mission: to empower professional excellence with world-class light and sight solutions, creating a safer and more capable world.

Attendees are invited to visit Olight at Hall 5A, Booth D001, to experience the future of tactical technology.

Hashtag: #Olight

The issuer is solely responsible for the content of this announcement.

About Olight

Founded in 2007, Olight is a global technology brand providing high-quality portable lighting and tactical tools. With a deep commitment to innovation and user-centric design, Olight is a trusted partner for law enforcement, military, and security professionals worldwide.

Noah to Report Third Quarter 2025 Unaudited Financial Results on November 25, 2025

By
Advertorial Desk
-

SHANGHAI, Nov. 13, 2025 /PRNewswire/ — Noah Holdings Limited (the “Company” or “Noah”) (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, after U.S. markets close on November 25, 2025.

Noah’s management team will hold an earnings conference call at 7:00 p.m. U.S. Eastern Time on Tuesday, November 25, 2025 (8:00 a.m. Beijing/Hong Kong Time on Wednesday, November 26, 2025). 

The conference call may be accessed with the following details:

Dial-in details:

Conference title:

Noah Holdings Limited Third Quarter 2025 Earnings Conference Call

Date/Time:                               

Tuesday, November 25, 2025, at 7:00 p.m., U.S. Eastern Time

Wednesday, November 26, 2025, at 8:00 a.m., Hong Kong Time

Dial in:

– Hong Kong Toll Free:

800-963976

– United States Toll Free:

1-888-317-6003

– Mainland China Toll Free:

4001-206115

– International Toll:

1-412-317-6061

Participant Password:

4879767

A telephone replay will be available starting approximately one hour after the end of the conference until December 2, 2025 at 1-855-669-9658 (US Toll Free) and 1-412-317-0088 (International Toll) with the access code 2159903.

A live and archived webcast of the conference call will be available on the Company’s investor relations website under the “News & Events” section at http://ir.noahgroup.com.

ABOUT NOAH HOLDINGS LIMITED

Noah Holdings Limited (NYSE: NOAH and HKEX: 6686) is a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors. In the first half of 2025, Noah distributed RMB33.1 billion (US$4.6 billion) of investment products. Through Gopher Asset Management and Olive Asset Management, Noah had assets under management of RMB145.1 billion (US$20.3 billion) as of June 30, 2025.

Noah’s domestic and overseas wealth management business primarily distributes private equity, public securities and insurance products denominated in RMB and other currencies. Noah’s network covers major cities in mainland China, as well as Hong Kong (China), New York, Silicon Valley, Singapore, and Los Angeles. The Company’s wealth management business had 464,631 registered clients as of June 30, 2025. Through its domestic and overseas asset management business operated by Gopher Asset Management and Olive Asset Management, Noah manages private equity, public securities, real estate, multi-strategies and other investments denominated in RMB and other currencies. The Company also operates other businesses.

For more information, please visit Noah at ir.noahgroup.com.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Noah may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in announcements, circulars or other publications made on the website of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Noah’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. These statements include, but are not limited to, estimates regarding the sufficiency of Noah’s cash and cash equivalents and liquidity risk. A number of factors could cause Noah’s actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: its goals and strategies; its future business development, financial condition and results of operations; the expected growth of the wealth management and asset management market in China and internationally; its expectations regarding demand for and market acceptance of the products it distributes; investment risks associated with investment products distributed to Noah’s investors, including the risk of default by counterparties or loss of value due to market or business conditions or misconduct by counterparties; its expectations regarding keeping and strengthening its relationships with key clients; relevant government policies and regulations relating to its industries; its ability to attract and retain qualified employees; its ability to stay abreast of market trends and technological advances; its plans to invest in research and development to enhance its product choices and service offerings; competition in its industries in China and internationally; general economic and business conditions globally and in China; and its ability to effectively protect its intellectual property rights and not to infringe on the intellectual property rights of others. Further information regarding these and other risks is included in Noah’s filings with the U.S. Securities and Exchange Commission and the Hong Kong Stock Exchange. All information provided in this press release and in the attachments is as of the date of this press release, and Noah does not undertake any obligation to update any such information, including forward-looking statements, as a result of new information, future events or otherwise, except as required under the applicable law.

Neusoft Recognized as 2025 Forbes China Go-International Series Top 30

By
Advertorial Desk
-

SHENYANG, China, Nov. 13, 2025 /PRNewswire/ — Recently, 2025 Forbes China Go-International 30&30 Series was officially released, and Neusoft Cloud Technology, a wholly-owned subsidiary of Neusoft Corporation (SSE：600718) was selected as one of the Top 30 Leading Brands for its excellent digital business & technology service capabilities and globalization practices, becoming the only technology company that provides comprehensive digital services on the list.

The Forbes China Go-International 30&30 Series Selection has been held for three consecutive years. It aims to recognize Chinese companies and representative figures excelling in global market expansion and has now become an authoritative benchmark for observing the globalization advancement of Chinese companies.

Neusoft has been actively committed to going global from the very beginning and has established a global business and service network covering multiple countries and regions, including Japan, the United States, Europe, and Southeast Asia. It serves over 20,000 clients across more than 110 countries and regions and has taken the lead or participated in the formulation of numerous national and international industry standards. Amid the rapid development of AI technology, Neusoft is expediting its dual strategy of “intelligence + globalization” to empower enterprises with a mature approach to enter the global market.

Neusoft Cloud Technology, as Neusoft’s wholly-owned subsidiary, specialized in providing digital business & technology services for global clients. Relying on Neusoft’s overall extensive global presence and exceptional software technology expertise, Neusoft Cloud Technology stands out with its core competencies in three areas: AI-driven digital experience, digital interaction, and digital infrastructure, which empowers enterprises to build global business competitiveness. Currently, Neusoft Cloud Technology has deployed a digital service and delivery network in more than 20 countries and regions worldwide, with exceptional response capabilities to serve global clients. It adopts a “China + International” dual-track model to achieve highly efficient global resource allocation and precise and locally-attuned market insights, thus forming an industry-leading intelligent service system.

Looking ahead, Neusoft will continue to empower its clients with data and AI, supporting them in achieving a full-chain overseas business expansion and integration into the global market. Meanwhile, Neusoft will continue to leverage the technologies, resources and experience accumulated in the global market to collaborate with clients, pursuing an upgrade from overseas business expansion to joint and deeper value creation, building a global value co-creation network to create more value and achieve mutual benefit and win-win growth.

For more information about Neusoft, please visit www.neusoft.com.

 

Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves

By
Advertorial Desk
-

Strategic realignment powering Bora’s dual-engine businesses model


HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025.

Quarterly Business and Financial Highlights

  • Company reported quarterly basic EPS of NT$5.09, with a loss per share of NT$1.49 from discontinued operations. Operating income reached NT$1,063 million and net income for continued operations came in at NT$822 million, resulting in quarterly EBITDA of NT$1,283 million, well on track to reclaim 2023 core P&L indicators.
  • By the end of 3Q25, Bora’s operational integration and strategic streamlining efforts have been fully executed, meeting all targeted objectives. This milestone has led to a record-high CDMO business profitability, clear evidence that Bora’s dual-engine model is now entering its next phase of balanced but scalable growth.
  • Fueled by expanded capacity and the addition of new dosage forms, Bora’s CDMO business grew 56.5% year-to-date through 3Q25, reaching over NT$7.3 billion and returning to a sequential growth trajectory.
  • Pharma sales revenues fluctuated as legacy inventory phased out, and new products are still awaiting approvals. Generics portfolio competitiveness remains a key focus area in the near term. Led by Vigafyde, Bora’s rare disease portfolio continued to gain impressive market share with the vigabatrin franchise across three dosage forms continues. The Company targets to file its next specialty pharma product by year end to accelerate the rare neurology disease business. The Company also targets to market branded Deflazacort tablets by 2025 year end as a new driver for the business.
  • The Company expects NTD to remain in the range of NTD 30-31 per USD for its operational planning.
  • Share capital increased 19.99% during the quarter from stock dividend distribution, employee stock option exercise and convertible bond conversions.
  • The Board approved Level-1 ADR issuance with each ADR share corresponding to 1/5 common share and total ADR issuance <10% of outstanding shares to enhanced market trust and investor service.


Mr. Bobby Sheng, Chairman of Bora Group, stated, “Bora executed a record level of post-merger CAPEX investment in 2025 and we are progressing in line with our strategic plan. We have expanded our Maryland aseptic fill/finish capacity by approximately 10% while solid and liquid dosage capacity in Minneapolis and Mississauga grew around 3%. The investments allowed Bora to increase our operational efficiency and increase revenue per headcount in the CDMO business by ~30% during the quarter compared to beginning of the year.

The CDMO backlog rose to US$296 million, driven by 27 new contracts and over 20 new molecules year-to-date, providing solid visibility into 2026 with 72% commercialized projects. Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio, while paving the way for selective in-house manufacturing of specialty assets in the U.S.

As we look ahead, Bora is entering a phase of disciplined expansion and broader global recognition. Across our CDMO facilities in Asia and North America, we continue to actively navigate tariff and geopolitical challenges and turn them into new opportunities, strengthening supply chain resilience, and deepening collaboration with multinational partners.

On the pharma sales side, we continue to shed legacy low margin generics, increase our cashflow, and focus on our high-value generics pipeline, with certain PIV opportunities progressing to maturity in 2026. We remain dedicated on enhancing portfolio quality and increasing our Branded assets through selective specialty drugs, in order to build a more predictable and margin-accretive revenue base that mitigates product commoditization and price degredation.

In parallel, we are expanding our capital-market reach into the United States through the OTCQX Level-1 ADR program. We believe the Bora ADR will improve access and transparency for global institutional investors, while enabling overseas employees to participate in Bora’s growth. With no dilution and increasing visibility, we are laying the foundation for a stronger and more global 2026, defined by scaled growth, operational synergies, and increasing investor confidence.

3Q2025 Operational Achievements & Full Year Outlook

Global CDMO Operations

Global CDMO Operations (excluding intercompany orders from Upsher-Smith) revenues arrived at NT$1.78 billion in the third quarter and back to the sequential growth zone, representing approximately 37.13% of total revenue. A total of 418 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 33%. Year-to-date, CDMO revenues grew 18.98% over last year and reached NT$5.27 billion. Bora continues to execute on expanding this customer base to enhance business visibility and stability.

  • As the Company ramps up its Maple Grove site, the momentum for U.S. manufacturing has been encouraging. Several clinical-stage clients are now transitioning into long-term strategic partnerships, with project scale and client size both increasing. Maple Grove is well positioned to be the Center of Excellence for scale-up and U.S. supply-chain integration for Bora.
  • Large molecule CDMO operation revenues saw nearly 50% increase over the previous quarter, driven by one new ADC client and several change orders in addition to Cipla’s own labeled product launch under the collaboration agreement. Positioned as a one-stop CDMO platform alongside Bora Pharmaceuticals, Bora Biologics is now fully accelerating its CDMO operations

Pharma Sales Operations

Pharma Sales Operations in the third quarter reached a revenue of NT$3.02 billion, down 6.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 62.83% of total revenues.

  • Discontinued loss per share (from the closure of the Plymouth production area) reflected the clearance sale of higher-cost inventories from Upsher-Smith’s legacy generics and internal supply transfer delayed by regulatory hurdles. These inventory clearance sales are now nearing completion. The greater-than-expected pricing pressure across our low margin generics reinforces the need to accelerate Bora’s transition toward higher-value and Branded specialty pharma products.
  • The Vigabatrin franchise market share expansion continues with the “total patient” indicator seeing breakthrough in October.
  • Bora continues to focus on DEE (Developmental and Epileptic Encephalopathies), where legacy compounds fail to meet significant unmet needs. The market is poised for new NCE entrants, expanding the addressable opportunity to roughly US$10 billion over the next 3–5 years. Bora aims to capture this growth through a Ready-to-Use 505(b)(2) pipeline and branded generics.

Recent Investor Conference

Bora will host an English online earnings call at 8:00 p.m. Taiwan time on Nov. 13th, 2025, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:30 p.m. on Nov. 14th, 2025. Both events will cover the company’s Q3’25 financial and business results and outlook.

English Online Earnings Presentation Link: https://events.q4inc.com/attendee/477519089

Bora will participate in the JP Morgan Healthcare Conference in January in San Francisco. For 1:1 meetings with management, please contact your JP Morgan representative.

Bora 2025 Earnings Schedule
Q4 2025: Expected in the 2nd week of March 2026

Hashtag: #BoraPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit .

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

Global Debut of FAMSCEND: Reshaping the Landscape of Agri-food Equipment Industry

By
Advertorial Desk
-

——FAMSUN Launched Its Premium New Brand

YANGZHOU, China, Nov. 13, 2025 /PRNewswire/ — On November 12, 2025, FAMSUN Co., Ltd., a globally leading player in the agri-food equipment industry, held a global launch ceremony for its premium brand FAMSCEND in Yangzhou, where its HQs are located. The event, themed “Innovate • Ascend • Nourish”, brought together over 160 industrial leaders and partners from the high-end food and pet food sectors in the world to witness the brand’s maiden voyage. It also marked FAMSUN’s official entry into the equipment industry for pet food and human healthy food, ushering in a strategic shift from scale leadership to value guidance.

Jack CHEN, President of FAMSUN, stated, “FAMSCEND will specialize in the processing equipment for pet food and human healthy foods, committed to creating sustainable value for global clients through four core capabilities – innovation, systematization, digitalization, and symbiosis.” Jason FAN, Vice President of FAMSUN, added, “The new brand will empower the global clients with more stable, efficient, and intelligent solutions.”

During the launch ceremony, seminars on cutting-edge technologies for the industry were also held, focusing on green manufacturing and intelligent trends. FAMSCEND’s comprehensive solutions and symbiotic concepts were highly recognized by its global clients.

Scenes of FAMSCEND’s global launch ceremony
Scenes of FAMSCEND’s global launch ceremony

 

Wintermute Reaches Strategic Cooperation with Leading Digital Trading Platform to Jointly Develop New Generation Quantitative Trading System

By
Advertorial Desk
-
LONDON, UK – Media OutReach Newswire – 13 November 2025 – Wintermute Trading Ltd., a globally leading cryptocurrency market maker, announced that it has reached a strategic cooperation with a renowned digital trading platform to jointly develop a new generation quantitative trading system. The two parties plan to integrate their respective advantages in algorithmic trading, liquidity provision, and market infrastructure to promote the development of digital asset trading technology.

As the core of the cooperation, Wintermute will jointly invest technical resources with its partner to build a high-performance, high-stability institutional-grade quantitative trading system, aiming to enhance trading efficiency and market liquidity, and provide a superior trading experience for a broader range of participants.

Wintermute stated that, as a global cryptocurrency market maker and liquidity provider, the company is always committed to promoting the development of the digital asset market through technological innovation, and maintains extensive cooperation with multiple leading global exchanges to jointly enhance market efficiency and stability.

Wintermute believes that deep cooperation with industry leaders is key to driving innovation and maturity in the cryptocurrency ecosystem. The company will leverage its accumulation in quantitative models and liquidity management, combined with the partner’s platform capabilities, to jointly set new technical standards for the market.

Disclaimer:
The content of this press release is published as general information and does not constitute any investment or trading advice.

Hashtag: #Wintermute

The issuer is solely responsible for the content of this announcement.

About Wintermute Trading Ltd.:

Wintermute is a leading cryptocurrency market maker and liquidity provider, focusing on DeFi and spot markets, utilizing advanced quantitative models and technical capabilities to provide liquidity support for hundreds of trading platforms and projects globally.

Yatsen Group Unveils Beauty Innovation Insight, Defining the Next Era of World-Class Beauty Science

By
Advertorial Desk
-

SHANGHAI, Nov. 13, 2025 /PRNewswire/ — Yatsen Group (NYSE: YSG), a leading multi-brand beauty company, has released Yatsen Group Beauty Innovation Insight — China’s first comprehensive report exploring innovation across beauty science, sustainability, and corporate responsibility.

The publication signals a milestone in the evolution of China’s beauty industry from brand storytelling to scientific leadership, and highlights Yatsen’s growing influence within the global research and development (R&D) community.

Yatsen Group Beauty Innovation Insight
Yatsen Group Beauty Innovation Insight

Defining Chinese Innovation from a Global Perspective

As the first white paper of its kind in China, Yatsen Group Beauty Innovation Insight centers on the theme of scientific innovation and includes six chapters spanning global R&D networks, technological breakthroughs, efficacy validation, and sustainable development.

At its launch ceremony in Shanghai’s Jing’an District, attended by government, academic, and industry leaders, Yatsen presented the white paper as both a reflection of its scientific progress and a statement of its global innovation roadmap.

David (Jinfeng) Huang, Founder, Chairman and CEO of Yatsen Group, delivers a keynote speech at the launch ceremony
David (Jinfeng) Huang, Founder, Chairman and CEO of Yatsen Group, delivers a keynote speech at the launch ceremony

“Our ambition to become a world-class technology-driven beauty pioneer is founded on years of consistent R&D investment and a commitment to scientific rigor,” said David (Jinfeng) Huang, Founder, Chairman, and CEO of Yatsen Group. “We are building a future where global research, global talent, and global markets intersect.”

Dr. Vania Leite, President of the International Federation of Societies of Cosmetic Chemists (IFSCC), contributed the report’s foreword:

“This is the first white paper from a Chinese beauty company to interpret cosmetic innovation through a global lens. Science knows no borders, and beauty knows no boundaries — this report serves as a bridge connecting China’s beauty science with the world.”

Yatsen Group Chief Scientific Officer Cheng Jing and IFSCC President Dr. Vania Leite reviewing the white paper
Yatsen Group Chief Scientific Officer Cheng Jing and IFSCC President Dr. Vania Leite reviewing the white paper

In August, Yatsen debuted the English edition of the white paper at the 35th IFSCC Congress — marking the first time Chinese cosmetic R&D achievements were presented in a comprehensive, internationally peer-reviewed format. Over the past four years, Yatsen has participated in major dermatological and cosmetic congresses, including the IFSCC, EADV, ADC, and WCD, strengthening China’s scientific voice in the global beauty dialogue.

From Lab to Market: Turning Science into Beauty

The Insight highlights how Yatsen transforms laboratory research into real consumer impact — an essential measure of innovation’s value.

Perfect Diary, Yatsen’s flagship brand, co-published the industry’s first Makeup Skinification Report with the China Association of Fragrance Flavor and Cosmetic Industries (CAFFCI) and Ruijin Hospital of Shanghai Jiao Tong University School of Medicine. The brand also launched its third-generation Biotec™ Technology, inspired by five Nobel Prize-recognized scientific discoveries that redefine how makeup enhances skin health.

In premium skincare, Galénic’s patented ActiveAnchor® technology has improved the dermal penetration of water-soluble Vitamin C, while EVE LOM has pioneered the world’s first Emotional Skincare Science framework, establishing new standards for mood-based skincare efficacy evaluation.

Yatsen’s Open Lab ecosystem connects more than 20 research collaborations across industry, academia, and medicine — including partnerships with Sun Yat-sen University, Fudan University, Ruijin Hospital, and Hôpital Saint-Louis in France. Since 2022, Yatsen has published 32 peer-reviewed papers in journals such as Science Bulletin and Nature Medicine, and has filed 252 global patents, including 78 invention applications.

“With a clear roadmap and deep interdisciplinary collaboration, we aim not only to innovate, but to lead how innovation is practiced in the beauty sector,” said Cheng Jing, Chief Scientific Officer of Yatsen Group.

Sustainable Innovation and Social Impact

Beyond R&D, Yatsen’s innovation philosophy extends to sustainability and social impact. The Group has published four consecutive ESG reports since 2021 and achieved an MSCI ESG Rating of A for two years running — the only Chinese beauty company to do so.

Yatsen Group 2024 Environmental, Social and Governance Report
Yatsen Group 2024 Environmental, Social and Governance Report

Aligned with China’s dual-carbon goals, Yatsen integrates low-carbon practices throughout its operations — from carbon audits and green sourcing to sustainable packaging. Perfect Diary’s “Slim Heel Lipstick” became one of the first beauty products in China to receive a Product Carbon Footprint Certification.

Premium brands have followed suit: EVE LOM now uses 100% FSC-certified recycled paper across all outer packaging, while Galénic has introduced refillable jar systems and removed printed inserts, cutting material usage by over 50%. The Galénic Skin Science Research Foundation further supports dermatological research globally, reinforcing Yatsen’s vision of beauty with purpose.

Galénic Couture Secret D'Excellence The Active Soft Cream
Galénic Couture Secret D’Excellence The Active Soft Cream

About Yatsen Group

Since its NYSE listing in 2020, Yatsen Group has made R&D the cornerstone of its strategy — investing more than RMB 600 million to date and maintaining R&D spending above 3% of annual revenue. The Group operates three global R&D centers in Shanghai, Guangzhou, and Toulouse (France), supported by six joint laboratories and over 20 international collaborations.

The Group’s “1-3-4-6-20 Global Research Network” includes:

  • 1 world-class biotech manufacturing facility
  • 3 proprietary R&D centers
  • 4 frontier research domains: Biotechnology, Scientific Skincare, Emotional Skincare, and Skin Data Science
  • 6 joint laboratories
  • 20+ academic and industry partnerships

Yatsen Global Innovation R&D Center
Yatsen Global Innovation R&D Center

As of mid-2025, skincare represents more than half of Yatsen’s total revenue — positioning the company among the top ten Chinese beauty enterprises by R&D investment and scientific capability.

“The future of beauty will be defined at the intersection of science, sustainability, and culture,” said David Huang. “Our mission is to help shape that future — responsibly, collaboratively, and globally.”

MP Group: Driving Health Innovation and Excellence

By
Advertorial Desk
-

BANGKOK, Nov. 13, 2025 /PRNewswire/ — MP Group (Thailand) Co., Ltd., a pioneering force in the Thai healthcare ecosystem, was proudly honored with the Corporate Excellence Award at the Asia Pacific Enterprise Awards (APEA) Thailand Chapter, organized by Enterprise Asia. This accolade celebrates the company’s remarkable journey, marked by two decades of unwavering commitment to medical innovation, holistic wellness, and empowering the community to “Live An Excellent Life.”

Founded in 2001, MP Group began as a distributor of medical diagnostic devices and has since evolved into a comprehensive healthcare solutions provider. Today, the company offers an extensive portfolio of over 1,000 SKUs, ranging from rapid diagnostic tests (RDTs) and clinical automation systems to cutting-edge technologies like next-generation sequencing (NGS) for precision medicine. By partnering with over 30 leading global manufacturers, MP Group ensures that healthcare providers nationwide have access to world-class diagnostic tools.

The company’s expansion demonstrates a strategic vision that goes beyond mere distribution. MP Group established the Health Plus Global Wellness Laboratory, a state-of-the-art service business certified with ISO 15189, solidifying its capacity for internationally recognized laboratory services. Furthermore, recognizing the importance of preventive health, MP Group has successfully ventured into the consumer health sector. Its Glass Skin skincare line is developed under the BCG (Bio-Circular-Green) Economy Model and uses scientifically-backed, eco-friendly ingredients. Expanding into nutraceuticals, home devices, and home testing solutions, MP Group brings critical screening and wellness tools closer to families, thereby playing a vital role in early detection and sustainable well-being.

MP Group’s success is underpinned by a robust corporate culture guided by its 3Ps framework: People, Process, and Profit. People are the company’s greatest strength, fostered by the PIE culture (Passion, Innovation, and Empathy) which encourages employees to be adaptable and collaborate. A process-driven mindset, focused on being “Fast and Accurate,” ensures efficiency, while Profit, driven by digital transformation and AI, enables continuous upskilling and long-term competitiveness.

Corporate responsibility is deeply embedded in MP Group’s operations. The company ensured nationwide access to diagnostic platforms and donated test kits to communities during the COVID-19 pandemic. It also supports various charitable initiatives, including donations to the Parkinson’s Patient Club and the Thai Red Cross Society.

Looking to the future, MP Group is committed to evolving into a fully digital healthcare organization, leveraging AI and automation to scale operations. By adhering to its core values and nurturing the next generation of leaders, MP Group ensures its mission—to deliver innovative, trustworthy, and accessible products that empower people to ‘Live An Excellent Life’—remains at the heart of its journey toward becoming a global healthcare leader.

About Enterprise Asia

Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine towards sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are an investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplift the economic status of people across Asia, and ensure a legacy of hope, innovation, and courage for future generations. Please visit www.enterpriseasia.org for more information.

About Asia Pacific Enterprise Awards

Launched in 2007, the Asia Pacific Enterprise Awards is the region’s most prestigious award for outstanding entrepreneurship, continuous innovation, and sustainable leadership. The Award provides a platform for companies and governments to recognize entrepreneurial excellence, hence spurring greater innovation, fair business practices, and growth in entrepreneurship. As a regional award, it groups together leading entrepreneurs as a powerful voice for entrepreneurship and serves as a by-invitation-only networking powerhouse. The program has grown to encompass 16 countries/regions and markets all over Asia. For further information, please visit www.apea.asia.

1...1,8181,8191,820...6,466Page 1,819 of 6,466